Stay updated on Cladribine, Idarubicin & Cytarabine for AML Clinical Trial
Sign up to get notified when there's something new on the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page.

Latest updates to the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedNew revision v3.4.2 was added to the history; revision v3.4.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision: v3.4.1 was added to the history and Revision: v3.4.0 was removed.SummaryDifference0.1%

- Check27 days agoChange DetectedGlossary is now shown and changes in the study record are color-coded (green for additions, red for deletions). The revision label was updated from v3.3.4 to v3.4.0, and the No FEAR Act data entry was removed.SummaryDifference0.8%

- Check42 days agoChange DetectedThe Record History now includes a new revision (v3.3.4) and removal of the previous revision (v3.3.3), which are minor internal versioning updates with no user-visible content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedThe latest version adds a Study Status entry and Revision: v3.3.3 dated 2025-12-17. The previous HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed on 2025-06-10.SummaryDifference0.5%

- Check91 days agoChange DetectedFooter revision label updated to v3.3.2; the previous v3.2.0 label was removed.SummaryDifference0.1%

Stay in the know with updates to Cladribine, Idarubicin & Cytarabine for AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page.